Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics

Patent metadata

Field	Value
Publication number	US-11051497-B2
Application number	US-201414220074-A
Country	US
Kind code	B2
Filing date	Mar 19, 2014
Priority date	Sep 19, 2011
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

The invention provides improved non-human vertebrates and non-vertebrate cells capable of expressing antibodies comprising human variable region sequences. The present invention is directed to the provision of long HCDR3s from non-human vertebrates and cells. The present invention is also directed to the provision of novel V, D and J pairings in immunoglobulin heavy and light chain loci. Novel, biased antibody diversities and potentially expanded diversities are provided. The invention also provides for novel and potentially expanded diversity or diversity that is biased towards variable gene usage common to antibodies useful for treating and/or preventing certain diseases or conditions, such as infectious diseases. The invention also provides methods of generating antibodies using such vertebrates, as well as the antibodies per se, therapeutic compositions thereof and uses.

First claim

The invention claimed is:

1. A method of isolating an antibody that binds a predetermined antigen, said antibody comprising a human heavy chain variable region, the method comprising
(a) providing a mouse whose genome comprises:
(i) an immunoglobulin heavy (IgH) chain locus comprising a plurality of human VH, one or more human D and one or more human JH gene segments at an endogenous locus upstream of and operably linked to a constant region;
wherein said plurality of human VH gene segments is selected from at least two of the group consisting of: IGHV3-7*01, IGHV3-9*01, IGHV7-4-1*01, IGHV1-3*01, IGHV4-4*02, IGHV3-13*01, IGHV3-23*04 and VH3-20*d01, and where one or more human D gene segments is selected from the group consisting of: IGHD2-2*01, IGHD3-9*01, IGHD3-10*01, IGHD6-13*01, IGHD4-17*01, IGHD6-19*01, IGHD3-22*01 and IGHD1-26*01,
said plurality of human VH gene segments each being capable of joining with a human D gene segment and a human JH gene segment to encode a variable region,
said plurality of human VH gene segments being capable of joining with a human D gene segment and a human JH segment to encode a variable region comprising a HCDR3 of 20 or more amino acids in length in said mouse;
said plurality of human VH gene segments capable of joining with a human D gene segment and a human JH segment to encode a variable region comprising a HCDR3 of 20 or more amino acids in length in said mouse and expresses an IgH heavy chain comprising a HCDR3 of 20 or more amino acids in length;

(ii) an immunoglobulin light (IgL) chain locus comprising one or more human VL gene segments and one or more human JL gene segments upstream of and operatively linked to a constant region;

(b) contacting said mouse with said antigen;
(c) removing B lymphocytes from the mouse and selecting a B lymphocyte expressing antibody that binds to the antigen;
(d) isolating an antibody expressed by the B lymphocytes, wherein in step (d) the antibody which is isolated has an HCDR3 length of at least 20 amino acids.

2. The method of claim 1 , comprising the step of isolating from said B lymphocyte nucleic acid encoding said antibody that binds said antigen.

3. The method of claim 1 , further comprising altering the antibody produced by the method of claim 1 .

4. The method of claim 1 , wherein said antibody is an IgG-type antibody.

5. A method of isolating an antibody that binds an antigen of an infectious disease pathogen, the method comprising
(a) providing a mouse according to step (a) of claim 1 ;
(b) contacting said mouse with said antigen;
(c) removing B lymphocytes from the mouse and selecting one or more B lymphocytes expressing antibodies that bind to the antigen;
(d) isolating an antibody expressed by the B lymphocytes;
wherein in step (d) the antibody which is isolated has an HCDR3 length of at least 20 amino acids.

6. The method of claim 5 , comprising the step of isolating from said B lymphocytes nucleic acid encoding said antibody that binds said antigen.

7. The method of claim 6 , wherein said antibody is an IgG-type antibody.

8. The method of claim 5 , further comprising altering the antibody produced by the method of claim 5 .

9. The method of claim 1 , wherein the human V region gene segments of said immunoglobulin heavy (IgH) chain locus step (a)(i) of said mouse genome consists of said a plurality of human VH, said one or more human D and said one or more human JH gene segments.

10. A method of isolating an antibody or fragment thereof, wherein said antibody binds a predetermined antigen, said antibody comprising a human heavy chain variable region, the method comprising:
(a) providing a mouse-whose genome comprises:
(i) an immunoglobulin heavy (IgH) chain locus comprising a plurality of human VH, one or more human D and one or more human JH gene segments at an endogenous locus upstream of and operably linked to a constant region;
wherein said plurality of human VH gene segments is selected from at least two of the group consisting of: IGHV3-7*01, IGHV3-9*01, IGHV7-4-1*01, IGHV1-3*01, IGHV4-4*02, IGHV3-13*01, IGHV3-23*04 and VH3-20*d01, and wherein said one or more human D gene segments is selected from the group consisting of: IGHD2-2*02, IGHD3-9*01, IGHD3-10*01, IGHD6-13*01, IGHD4-17*01, IGHD6-19*01, IGHD3-22*01 and IGHD1-26*01,
wherein said plurality of human VH gene segments comprises: IGHV3-7*01, IGHV3-9*01, IGHV7-4-1*01, IGHV1-3*01, IGHV4-4*02, IGHV3-13*01, IGHV3-23*04, and VH3-20*d01;

said plurality of human VH gene segments each being capable of joining with a human D gene segment and a human JH segment to encode a variable region;
(ii) an immunoglobulin light (IgL) chain locus comprising one or more human VL gene segments and one or more human JL gene segments upstream of and operatively linked to a constant region;

(b) contacting said mouse with said antigen;
(c) isolating nucleic acid from the tissue or blood of said contacted mouse of (b), wherein said nucleic comprises nucleic acid encoding said antibody, wherein said antibody comprises a human Ig chain variable region and binds said antigen,
(d) expressing from said nucleic acid one or more of:
(i) an IgH chain or fragment thereof, of said antibody that binds said antigen, wherein said IgH chain or fragment thereof, comprises a human IgH chain variable region,
(ii) an IgL chain or fragment thereof, of said antibody that binds said antigen, wherein said IgL chain or fragment thereof, comprises a human IgL chain variable region, or
(iii) the IgH chain or fragment thereof, of (d)(i) and the IgL chain or fragment thereof, of (d)(ii),

(e) isolating an antibody or fragment thereof, wherein said isolated antibody or fragment thereof, comprises the IgH chain or fragment thereof, of (d)(i) and/or the IgL chain or fragment thereof, of (d)(ii), and wherein said antibody contains a said human Ig variable region and binds said antigen.

11. A method of isolating an antibody that binds a predetermined antigen, said antibody comprising a human heavy chain variable region, the method comprising
(a) providing a mouse whose genome comprises:
(i) an immunoglobulin heavy (IgH) chain locus comprising a plurality of human VH, one or more human D and one or more human JH gene segments at an endogenous locus upstream of and operably linked to a constant region;
wherein said plurality of human VH gene segments is selected from at least two of the group consisting of: IGHV3-7*01, IGHV3-9*01, IGHV7-4-1*01, IGHV1-3*01, IGHV4-4*02, IGHV3-13*01, IGHV3-23*04 and VH3-20*d01, and where one or more human D gene segments is selected from the group consisting of: IGHD2-2*01, IGHD3-9*01, IGHD3-10*01, IGHD6-13*01, IGHD4-17*01, IGHD6-19*01, IGHD3-22*01 and IGHD1-26*01,
wherein said plurality of human VH gene segments comprises: IGHV3-7*01, IGHV3-9*01, IGHV7-4-1*01, IGHV1-3*01, IGHV4-4*02, IGHV3-13*01, IGHV3-23*04, and VH3-20*d01;
said plurality of human VH gene segments each being capable of joining with a human D gene segment and a human JH gene segment to encode a variable region,
(ii) an immunoglobulin light (IgL) chain locus comprising one or more human VL gene segments and one or more human JL gene segments upstream of and operatively linked to a constant region;

(b) contacting said mouse with said antigen;
(c) removing B lymphocytes from the mouse and selecting a B lymphocyte expressing antibody that binds to the antigen;
(d) isolating an antibody expressed by the B lymphocytes.

12. The method of claim 1 , wherein said one or more human D gene segments comprises IGHD2-2*02, IGHD3-9*01, IGHD3-10*01, IGHD6-13*01, IGHD4-17*01, IGHD6-19*01, IGHD3-22*01 and IGHD1-26*01.

Assignees

• Kymab Ltd

Inventors

• Friedrich Glenn
• Lee E-Chiang
• Clube Jasper
• England Nicholas

Classifications

• C07K16/114

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• C07K16/108

  Orthomyxoviridae (F), e.g. influenza virus · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C07K16/1242

  from Pasteurellaceae (F), e.g. Haemophilus influenza · CPC title

• C07K16/1232

  Escherichia (G) · CPC title